These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28729220)

  • 1. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
    Gould RW; Grannan MD; Gunter BW; Ball J; Bubser M; Bridges TM; Wess J; Wood MW; Brandon NJ; Duggan ME; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2018 Jan; 128():492-502. PubMed ID: 28729220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.
    Bubser M; Bridges TM; Dencker D; Gould RW; Grannan M; Noetzel MJ; Lamsal A; Niswender CM; Daniels JS; Poslusney MS; Melancon BJ; Tarr JC; Byers FW; Wess J; Duggan ME; Dunlop J; Wood MW; Brandon NJ; Wood MR; Lindsley CW; Conn PJ; Jones CK
    ACS Chem Neurosci; 2014 Oct; 5(10):920-42. PubMed ID: 25137629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.
    Gould RW; Nedelcovych MT; Gong X; Tsai E; Bubser M; Bridges TM; Wood MR; Duggan ME; Brandon NJ; Dunlop J; Wood MW; Ivarsson M; Noetzel MJ; Daniels JS; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2016 Mar; 102():244-53. PubMed ID: 26617071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
    Byun NE; Grannan M; Bubser M; Barry RL; Thompson A; Rosanelli J; Gowrishankar R; Kelm ND; Damon S; Bridges TM; Melancon BJ; Tarr JC; Brogan JT; Avison MJ; Deutch AY; Wess J; Wood MR; Lindsley CW; Gore JC; Conn PJ; Jones CK
    Neuropsychopharmacology; 2014 Jun; 39(7):1578-93. PubMed ID: 24442096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M
    Grannan MD; Mielnik CA; Moran SP; Gould RW; Ball J; Lu Z; Bubser M; Ramsey AJ; Abe M; Cho HP; Nance KD; Blobaum AL; Niswender CM; Conn PJ; Lindsley CW; Jones CK
    ACS Chem Neurosci; 2016 Dec; 7(12):1706-1716. PubMed ID: 27617634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice.
    Cieślik P; Radulska A; Pelikant-Małecka I; Płoska A; Kalinowski L; Wierońska JM
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.
    Gregory KJ; Herman EJ; Ramsey AJ; Hammond AS; Byun NE; Stauffer SR; Manka JT; Jadhav S; Bridges TM; Weaver CD; Niswender CM; Steckler T; Drinkenburg WH; Ahnaou A; Lavreysen H; Macdonald GJ; Bartolomé JM; Mackie C; Hrupka BJ; Caron MG; Daigle TL; Lindsley CW; Conn PJ; Jones CK
    J Pharmacol Exp Ther; 2013 Nov; 347(2):438-57. PubMed ID: 23965381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice.
    Gould RW; Dencker D; Grannan M; Bubser M; Zhan X; Wess J; Xiang Z; Locuson C; Lindsley CW; Conn PJ; Jones CK
    ACS Chem Neurosci; 2015 Oct; 6(10):1683-95. PubMed ID: 26176846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscarinic receptor M
    Dall C; Weikop P; Dencker D; Molander AC; Wörtwein G; Conn PJ; Fink-Jensen A; Thomsen M
    Drug Alcohol Depend; 2017 Jul; 176():154-161. PubMed ID: 28544993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the mGlu
    Yohn SE; Foster DJ; Covey DP; Moehle MS; Galbraith J; Garcia-Barrantes PM; Cho HP; Bubser M; Blobaum AL; Joffe ME; Cheer JF; Jones CK; Lindsley CW; Conn PJ
    Mol Psychiatry; 2020 Nov; 25(11):2786-2799. PubMed ID: 30116027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior.
    Choy KH; Shackleford DM; Malone DT; Mistry SN; Patil RT; Scammells PJ; Langmead CJ; Pantelis C; Sexton PM; Lane JR; Christopoulos A
    J Pharmacol Exp Ther; 2016 Nov; 359(2):354-365. PubMed ID: 27630144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized Administration of the M
    Cikowski J; Holt C; Arthur B; Smith M; Gonzalez S; Lindsley CW; Niswender CM; Gogliotti RG
    ACS Chem Neurosci; 2022 Jul; 13(13):1891-1901. PubMed ID: 35671352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.
    Watt ML; Rorick-Kehn L; Shaw DB; Knitowski KM; Quets AT; Chesterfield AK; McKinzie DL; Felder CC
    Neuropsychopharmacology; 2013 Dec; 38(13):2717-26. PubMed ID: 23907402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
    Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
    J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of M
    Cadeddu R; Braccagni G; Branca C; van Luik ER; Pittenger C; Thomsen MS; Bortolato M
    Br J Pharmacol; 2024 Sep; 181(17):3064-3081. PubMed ID: 38689378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutual activation of glutamatergic mGlu
    Cieślik P; Woźniak M; Rook JM; Tantawy MN; Conn PJ; Acher F; Tokarski K; Kusek M; Pilc A; Wierońska JM
    Psychopharmacology (Berl); 2018 Oct; 235(10):2897-2913. PubMed ID: 30054675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.
    Suryavanshi PS; Ugale RR; Yilmazer-Hanke D; Stairs DJ; Dravid SM
    Br J Pharmacol; 2014 Feb; 171(3):799-809. PubMed ID: 24236947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive allosteric modulation of M
    Yohn SE; Conn PJ
    Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.